Revance Therapeutics, Inc. — Revenue by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/88f7b582-f5fb-4d7a-b3c0-189c831fc673/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2023 | $234.0M | 2023-01-01 – 2023-12-31 | evidence 0001479290-24-000038 |
| FY 2022 | $132.6M | 2022-01-01 – 2022-12-31 | evidence 0001479290-23-000028 |
| FY 2021 | $77.8M | 2021-01-01 – 2021-12-31 | evidence 0001479290-22-000034 |
| FY 2020 | $15.3M | 2020-01-01 – 2020-12-31 | evidence 0001479290-21-000057 |
| FY 2019 | $413.0k | 2019-01-01 – 2019-12-31 | evidence 0001479290-21-000057 |
| FY 2018 | $3.7M | 2018-01-01 – 2018-12-31 | evidence 0001479290-21-000057 |
| FY 2017 | $262.0k | 2017-01-01 – 2017-12-31 | evidence 0001479290-18-000038 |
| FY 2016 | $300.0k | 2016-01-01 – 2016-12-31 | evidence 0001479290-17-000013 |
| FY 2015 | $300.0k | 2015-01-01 – 2015-12-31 | evidence 0001479290-16-000031 |
| FY 2014 | $383.0k | 2014-01-01 – 2014-12-31 | evidence 0001628280-15-001461 |
| FY 2013 | $5.4M | 1999-08-10 – 2014-03-31 | evidence 0001193125-14-199234 |
| FY 2012 | $150.0k | 2012-01-01 – 2012-12-31 | evidence 0001628280-15-006314 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Revance Therapeutics, Inc. — all facts · Net Income · Operating Income